P-257

MAILPAN® (MAcro-encapsulation of PANcreatic Islets), a bioartificial pancreas to treat type 1 diabetes

S. Sigrist, R. BouAoun
Defymed, Strasbourg, France

Objective: MAILPAN’s project aims to develop a macro-encapsulation device in order to treat type 1 diabetes patients. This medical device is devoted to encapsulate insulin-secretory cells after being implanted in the intraperitoneal cavity of patients. Yet, it has the functions of a bioartificiel pancreas.

Methods: The innovativeness is supported by the following aspects: 1) the use of semi-permeable membranes allowing the exchange of nutrients/glucose and Insulin, and inhibiting the killing of the cells by the immune system; 2) surface functionalization in order to induce the vascularization of the device and inhibit any inflammation; 3) Optimized dimensions in order to implant a sufficient number of islets/cells; 4) the use of a diffusion chamber allowing emptying the device from the dead cells and filling it with new fresh cells.

Results: MAILPAN® prototype has been developed during the past years. We have shown that: 1) we can implant a high number of cells sufficient to establish a normo-glycemia; 2) we are able to fill/empty the device which allows the replacement of dead cells; 3) pre-implantation of the device one month before cells' filling decreases by 50% the cells death; 4) the membrane functionnalization allows the cells to exchange rapidly with the surrounding tissues; 5) the biocompatibility of the device was validated on rats and pigs.

Conclusion: MAILPAN’s project is a great opportunity for laboratories in order to assess the function of their insulin-secretory cells in clinical assays.

P-257

MAILPAN® (MAcro-encapsulation of PANcreatic Islets), a bioartificial pancreas to treat type 1 diabetes

S. Sigrist, R. BouAoun
Defymed, Strasbourg, France

Objective: MAILPAN’s project aims to develop a macro-encapsulation device in order to treat type 1 diabetes patients. This medical device is devoted to encapsulate insulin-secretory cells after being implanted in the intraperitoneal cavity of patients. Yet, it has the functions of a bioartificiel pancreas.

Methods: The innovativeness is supported by the following aspects: 1) the use of semi-permeable membranes allowing the exchange of nutrients/glucose and Insulin, and inhibiting the killing of the cells by the immune system; 2) surface functionalization in order to induce the vascularization of the device and inhibit any inflammation; 3) Optimized dimensions in order to implant a sufficient number of islets/cells; 4) the use of a diffusion chamber allowing emptying the device from the dead cells and filling it with new fresh cells.

Results: MAILPAN® prototype has been developed during the past years. We have shown that: 1) we can implant a high number of cells sufficient to establish a normo-glycemia; 2) we are able to fill/empty the device which allows the replacement of dead cells; 3) pre-implantation of the device one month before cells' filling decreases by 50% the cells death; 4) the membrane functionnalization allows the cells to exchange rapidly with the surrounding tissues; 5) the biocompatibility of the device was validated on rats and pigs.

Conclusion: MAILPAN’s project is a great opportunity for laboratories in order to assess the function of their insulin-secretory cells in clinical assays.